Licensing
Cosmederm's proprietary compounds can be added to existing topical products to create demonstrably superior, and patent protected, formulations. We welcome business relationships with strategic partners interested in licensing our technology for use in their cosmetic, OTC drug or Rx drugs. To contact us about partnering opportunities e-mail This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Our technology's anti-inflammatory/anti-irritant/anti-itch properties can improve existing products by allowing increased levels of active ingredients without added irritation. In addition, it can provide immediate anti-itch efficacy where such efficacy is latent or lacking altogether. Examples of products that can be improved by the addition of our compounds include:
- anti aging products (AHAs, BHAs, retinoids)
- acne products
- anti-itch products
- anti-fungals
- hydrocortisone
- sunburn pain product
- sunscreen with sunburn pain relief
- dandruff shampoo
- deodorants/anti-perspirants
- bug repellants and bug bite treatments
- poison ivy/oak/sumac treatments
The core technology has two primary activities:
- Selective inhibition of Type C nociceptors that transmit itching, burning pain and stinging sensations without numbness of conventional local anesthetics. Full clinical benefits are evident within several minutes after application.
- Anti-inflammatory activity derived from two distinct mechanisms:
- Inhibition of neurogenic inflammation and release of Substance P, Neurokinin A & Calcitonin Gene-Related Peptide (CGRP).
- Inhibition of keratinocyte release of Tumor Necrosis Factor-Alpha (TNF-alpha), Interleukin-1 alpha (IL-1 alpha) and IL-6.
Unlike many early-stage pharmaceutical development technologies, this technology has been tested in over 1000 patients in well-controlled human clinical trials and the results from these clinical trials have been replicated by among the world’s leading academic and commercial Dermatology experts and published in leading peer-reviewed medical journals. These studies, physician clinical observations and the technology’s mechanism of action suggest that it will be safe and effective for the following applications:
- Allergic Skin Disease (Immediate-Type, IgE-mediated & Delayed-Type (DTH))
- Histamine-Induced Pruritus
- Acid-Induced Burns (pH 0.6 to pH 4) (Alpha-Hydroxy (AHA) and Beta-Hydroxy Acids (BHA), Ascorbic Acid, Antiperspirants (e.g. Aluminum-zirconium mixtures)
- Base-Induced Burns (Depilatories, Hair Wave Products to pH 13)
- Environmental Irritants found at home, in industrial settings and outdoors
- Vesicant / Blistering Agents Used in Chemical Warfare
- Ultraviolet-Induced Burning Pain and Pruritus
- Thermal Burn Pain, Pruritus & Blistering
- Pruritus from atopic dermatitis, psoriasis, allergic and immunoinflammatory disorders
- Neuropathic Pain from:
- - Diabetes
- - Traumatic nerve damage
- - Viral infection (Herpes Zoster - “Shingles”)
FDA and European Union safety reviews demonstrate an exemplary safety record.